AbCellera Biologics Inc.
NASDAQ:ABCL
2.75 (USD) • At close September 18, 2024
Overview | Financials
Numbers are in millions (except for per share data and ratios) USD.
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|---|
| Revenue
| 38.025 | 485.424 | 375.203 | 233.155 | 11.612 | 8.831 |
| Cost of Revenue
| 30.894 | 66.436 | 45.516 | 27.143 | 10.113 | 5.803 |
| Gross Profit
| 7.131 | 418.988 | 329.687 | 206.012 | 1.499 | 3.028 |
| Gross Profit Ratio
| 0.188 | 0.863 | 0.879 | 0.884 | 0.129 | 0.343 |
| Reseach & Development Expenses
| 175.658 | 107.879 | 62.062 | 29.393 | 10.113 | 5.803 |
| General & Administrative Expenses
| 60.999 | 55.485 | 41.848 | 11.91 | 2.749 | 2.151 |
| Selling & Marketing Expenses
| 14.18 | 11.27 | 6.913 | 3.842 | 1.263 | 0.712 |
| SG&A
| 75.179 | 66.755 | 48.761 | 15.752 | 4.012 | 2.863 |
| Other Expenses
| 6.776 | 17.289 | -3.035 | -3.484 | -0.17 | -0.676 |
| Operating Expenses
| 261.077 | 191.923 | 107.788 | 41.661 | 13.954 | 7.99 |
| Operating Income
| -237.207 | 216.511 | 204.413 | 156.031 | -4.117 | -0.753 |
| Operating Income Ratio
| -6.238 | 0.446 | 0.545 | 0.669 | -0.355 | -0.085 |
| Total Other Income Expenses Net
| 6.776 | 22.588 | 14.736 | 1.802 | 1.906 | -0.362 |
| Income Before Tax
| -174.029 | 239.099 | 219.149 | 157.833 | -2.211 | 0.309 |
| Income Before Tax Ratio
| -4.577 | 0.493 | 0.584 | 0.677 | -0.19 | 0.035 |
| Income Tax Expense
| -27.631 | 80.58 | 65.685 | 38.915 | 0.209 | 1.274 |
| Net Income
| -146.398 | 158.519 | 153.464 | 118.918 | -2.42 | 0.309 |
| Net Income Ratio
| -3.85 | 0.327 | 0.409 | 0.51 | -0.208 | 0.035 |
| EPS
| -0.51 | 0.56 | 0.56 | 0.44 | -0.016 | 0.001 |
| EPS Diluted
| -0.51 | 0.5 | 0.48 | 0.44 | -0.016 | 0.001 |
| EBITDA
| -192.158 | 276.246 | 242.479 | 169.915 | -0.341 | 1.801 |
| EBITDA Ratio
| -5.053 | 0.569 | 0.646 | 0.729 | -0.029 | 0.204 |